Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen C Harris

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Journal of Clinical Pharmacology|February 12, 2016
Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy SubjectsYi Wang, Alessandra Cipriano, Catherine Munera, et al.
Journal of Clinical Pharmacology|May 23, 2002
The pharmacokinetics and safety of single escalating oral doses of eletriptanAjit K Shah, Stephen C Harris, Catherine Greenhalgh, et al.
Journal of Clinical Pharmacology|August 12, 2025
Reversal of Fentanyl-Induced Respiratory Depression in Healthy Subjects by Intramuscular Nalmefene Administered by Auto-Injector Versus Intranasal NaloxoneAlessandra Cipriano, Ellie He, Manjunath Shet, et al.
Clinical Drug Investigation|May 17, 2013
Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adultsPeter J Perrino, Salvatore V Colucci, Glen Apseloff, et al.
Journal of Psychopharmacology (Oxford, England)|June 21, 2013
Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potentialEdward M Sellers, Peter J Perrino, Salvatore V Colucci, et al.
Postgraduate Medicine|December 9, 2016
Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trialsStephen C Harris, Joel Morganroth, Steven R Ripa, et al.
Journal of Clinical Pharmacology|September 30, 2024
Time Course of Reversal of Fentanyl-Induced Respiratory Depression in Healthy Subjects by Intramuscular Nalmefene and Intramuscular and Intranasal NaloxoneAlessandra Cipriano, Glen Apseloff, Ram P Kapil, et al.
British Journal of Clinical Pharmacology|August 27, 2025
Efficacy and safety of a selective partial agonist for nociception/orphanin-FQ peptide (NOP) receptors in patients with insomnia disorderGarth T Whiteside, Ellie He, S Shet Manjunath, et al.
Clinical Drug Investigation|April 24, 2014
Abuse potential of intravenous oxycodone/naloxone solution in nondependent recreational drug usersSalvatore V Colucci, Peter J Perrino, Megan Shram, et al.
Drug Discovery Today. Technologies|July 2, 2014
An integrated bioinformatics infrastructure essential for advancing pharmacogenomics and personalized medicine in the context of the FDA's Critical Path InitiativeWeida Tong, Stephen C Harris, Hong Fang, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Journal of Clinical Pharmacology|February 12, 2016
Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy SubjectsYi Wang, Alessandra Cipriano, Catherine Munera, et al.
Journal of Clinical Pharmacology|May 23, 2002
The pharmacokinetics and safety of single escalating oral doses of eletriptanAjit K Shah, Stephen C Harris, Catherine Greenhalgh, et al.
Journal of Clinical Pharmacology|August 12, 2025
Reversal of Fentanyl-Induced Respiratory Depression in Healthy Subjects by Intramuscular Nalmefene Administered by Auto-Injector Versus Intranasal NaloxoneAlessandra Cipriano, Ellie He, Manjunath Shet, et al.
Clinical Drug Investigation|May 17, 2013
Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adultsPeter J Perrino, Salvatore V Colucci, Glen Apseloff, et al.
Journal of Psychopharmacology (Oxford, England)|June 21, 2013
Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potentialEdward M Sellers, Peter J Perrino, Salvatore V Colucci, et al.
Postgraduate Medicine|December 9, 2016
Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trialsStephen C Harris, Joel Morganroth, Steven R Ripa, et al.
Journal of Clinical Pharmacology|September 30, 2024
Time Course of Reversal of Fentanyl-Induced Respiratory Depression in Healthy Subjects by Intramuscular Nalmefene and Intramuscular and Intranasal NaloxoneAlessandra Cipriano, Glen Apseloff, Ram P Kapil, et al.
British Journal of Clinical Pharmacology|August 27, 2025
Efficacy and safety of a selective partial agonist for nociception/orphanin-FQ peptide (NOP) receptors in patients with insomnia disorderGarth T Whiteside, Ellie He, S Shet Manjunath, et al.
Clinical Drug Investigation|April 24, 2014
Abuse potential of intravenous oxycodone/naloxone solution in nondependent recreational drug usersSalvatore V Colucci, Peter J Perrino, Megan Shram, et al.
Drug Discovery Today. Technologies|July 2, 2014
An integrated bioinformatics infrastructure essential for advancing pharmacogenomics and personalized medicine in the context of the FDA's Critical Path InitiativeWeida Tong, Stephen C Harris, Hong Fang, et al.
Pageof 4